The FDA's approval of FluMist for at-home use marks a significant development, allowing needle-averse individuals access to an effective nasal spray vaccine for influenza.
Dr. Peter Marks emphasized that this new option provides families with greater convenience and accessibility, showcasing the importance of clear instructions and feasibility for at-home vaccination.
AstraZeneca is rolling out a FluMist Home website where individuals can complete a questionnaire reviewed by a pharmacist before having the vaccine shipped directly to them.
The Centers for Disease Control and Prevention reported that hospitalizations from flu have fluctuated from 100,000 to 700,000 annually, underscoring the vaccine's potential impact.
Collection
[
|
...
]